Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib by Rijavec E, Biello F, Indini A, Grossi F, Genova C

Get full text

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer by Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S

Get full text

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for meso... by O'Brien, M, Gaafar, R, Popat, S, Grossi, F, Price, A, Talbot, D, Cufer, T, Ottensmeier, C, Danson, S, Pallis, A, Hasan, B, Van Meerbeeck, J, Baas, P

A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line tre... by Talbot, D, Blackhall, F, Kowalski, D, Ramlau, R, Bepler, G, Grossi, F, Lerchenmuller, C, Pinder, M, Mezger, J, Danson, S, Callies, S, Andre, V, Das, M, Lahn, M, Natale, R

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients... by Natale, R, Blackhall, F, Kowalski, D, Ramlau, R, Bepler, G, Grossi, F, Lerchenmüller, C, Pinder-Schenck, M, Mezger, J, Danson, S, Gadgeel, S, Summers, Y, Callies, S, André, V, Das, M, Lahn, M, Talbot, D